2023 was a tricky yr with the biopharma sector, with various companies downsizing and restructuring their workforces to stay afloat. You'll find indications of recovery, as mergers and acquisitions picked up through the pharmaceutical and everyday living sciences field while in the latter A part of 2023 and also have https://sites.google.com/view/bio-sites/blog